Download as pdf or txt
Download as pdf or txt
You are on page 1of 60

7/16/2020

Equipment Cleaning Process


Development – Where and How
to Start ?
Presented by Richard Chai
STERIS Corporation
Richard_Chai@steris.com

ISPE Indonesia,
16 Jul 2020

Agenda – Part 1

• Lifecycle approach to Cleaning


Validation
• Cleaning design space
• Soil characterization
• Cleaning mechanisms and critical
cleaning parameters
• Optimization of cleaning parameters

Connecting Pharmaceutical Knowledge ispe.org

1
7/16/2020

What is Cleaning Process


Development ?
Cleaning Process
Objective
Development

Soil Successful cleaning


Characterization validation

Cleaning
Optimization of cleaning
parameters /
process
methods

Residue detection
Minimized product cross‐
methods /
contamination
acceptance criteria

Connecting Pharmaceutical Knowledge ispe.org

Regulations
• FDA 21 Code of Federal Regulations (CFR)
• US FDA, Biotech Inspection Guide (11/91)
• US FDA, Guide to Inspections Validation of Cleaning
Processes (1993)
• Pharmaceutical Inspection Convention/Co-operation
Scheme (PIC/S)
 PE 009-14 Part I (2018) - Guide to Good Manufacturing Practice for
Medicinal Products Part I
 PI 052-1 (Jun 2020) - Inspection of Health Based Exposure Limit (HBEL)
Assessment and Use In Quality Risk Management
 PI 053-1 (Jun 2020) Questions and Answers on Implementation of Risk-
Based Prevention of Cross Contamination in Production and ‘Guideline
on Setting Health-Based Exposure Limits for Use in Risk Identification in
the Manufacture of Different Medicinal Products in Shared Facilities’

Connecting Pharmaceutical Knowledge ispe.org

2
7/16/2020

Regulations

• EU Guidelines for Good Manufacturing Practice


for Medicinal Products for Human and
Veterinary Use Medicinal Products for Human
use
• Part 1 Chapter 3 (2014): Equipment and Premises
• Part 1 Chapter 5 (2014): Production
• Annex 1 (2008): Manufacture of Sterile Medicinal
Products
• Annex 1 draft v12 (2020)
• Annex 15 (2015): Qualification and Validation

Connecting Pharmaceutical Knowledge ispe.org

21 CFR 211.67
• Part 211.67 Equipment Cleaning and
Maintenance
• Written procedures shall be established and
followed for cleaning and maintenance of
equipment…
• A description in sufficient detail of the
methods, equipment, and materials used in
cleaning and maintenance operation…

Connecting Pharmaceutical Knowledge ispe.org

3
7/16/2020

PIC/S PE 009-14 Part I (2018)


• Prevention of cross-contamination in
production
• Cross-contamination should be prevented by
attention to design of the premises and
equipment as described in Chapter 3.
• This should be supported by attention to
process design and implementation of any
relevant technical or organizational measures,
including effective and reproducible cleaning
processes to control risk of cross-
contamination.
Connecting Pharmaceutical Knowledge ispe.org

Chapter 5 - Production

• Prevention of cross-contamination in
production
• Cross-contamination should be prevented by
attention to design of the premises and
equipment as described in Chapter 3. This
should be supported by attention to process
design and implementation of any relevant
technical or organizational measures, including
effective and reproducible cleaning processes
to control risk of cross contamination.

Connecting Pharmaceutical Knowledge ispe.org

4
7/16/2020

Warning Letter
Failure to have adequate cleaning procedures to prevent contamination
or carry-over of a material that would alter the quality of the API.
Your firm uses shared equipment for the API you manufacture. Data
from cleaning verification and validation studies found that your
cleaning procedures were ineffective. For example, our investigator
discovered that 105 of (b)(4) cleaning verification samples taken
between 2015 and the start of our 2016 inspection failed your firm’s
specification of no more than (b)(4) ppm for residual drug.
After obtaining failing cleaning verification results, you repeated
cleaning until you obtained passing verification results. Your firm failed
to investigate recurring cleaning procedure ineffectiveness and did not
remediate the deficient procedures.
Warning Letter 320-17-23 (Feb 2017)

Connecting Pharmaceutical Knowledge ispe.org

Warning Letters
1. Your firm failed to establish and follow adequate written
procedures for cleaning and maintenance of equipment (21
CFR 211.67(b)).

You are a contract manufacturer who makes several


products for multiple customers. Your cleaning and
maintenance program is inadequate. For example,
deficiencies in your program included extended hold times
for dirty equipment, such as your encapsulator, that were
unsupported by validation data. In addition, you did not
establish timeframes for replacing parts and cleaning your
tablet coating equipment.
Warning Letter 566492 (Feb 2019)

Connecting Pharmaceutical Knowledge ispe.org

10

5
7/16/2020

Lifecycle Approach to Cleaning Validation

Connecting Pharmaceutical Knowledge ispe.org

11

Lifecycle Approach to Cleaning


Validation

• Process defined through development & scale‐up activities


Process • Process variables identified & critical variable limits defined
Design

• Process designed evaluation on reproducibility


Process • Verify process produces expected results
Qualification

• Critical variables monitored


Continuous • Process remain in state of control
Verification

Lopolito and Rivera, “Cleaning Validation: Process Life Cycle Model”, Chapter 9 in Contamination Control in Healthcare Product Manufacturing, Volume 3,
PDA/DHI Publishing (2014)

Connecting Pharmaceutical Knowledge ispe.org

12

6
7/16/2020

Lifecycle Model – Stage 1

Cleaning Critical Cleaning Residue


Method Parameters Detection
• Clean in place • Cleaning • Residue type
• Clean out of agent • Sampling
place screening method
• Manual • Lab scale • Analytical
Cleaning study (TACCT) method
• Pilot plant /
field trials

Lopolito and Rivera, “Cleaning Validation: Process Life Cycle Model”, Chapter 9 in Contamination
Control in Healthcare Product Manufacturing, Volume 3, PDA/DHI Publishing (2014)

Connecting Pharmaceutical Knowledge ispe.org

13

Lifecycle Model – Stage 1


Acceptance Grouping Process
Criteria Strategy Equipment
• Residue • Equipment • Sanitary
limits – • Product design
Product & • Equipment • Surface
Cleaning train finishes
agent • MOC
• Visual • Other CIP
inspection design
concepts

Lopolito and Rivera, “Cleaning Validation: Process Life Cycle Model”, Chapter 9 in Contamination
Control in Healthcare Product Manufacturing, Volume 3, PDA/DHI Publishing (2014)

Connecting Pharmaceutical Knowledge ispe.org

14

7
7/16/2020

Designing a Cleaning Process –


Where to Start ?

• Need to know and understand:

Process flow Process Process soils Components


Equipment of cleaning

Connecting Pharmaceutical Knowledge ispe.org

15

Cleaning Methods
• Static immersion
• Agitated immersion
• Solvent reflux
• Automated parts washer
• Ultrasonic
• High pressure water jet
• Manual
• Sink scrub (brush)
• Wipe
• High pressure spray
• Foamers
• Clean-in-Place (CIP)

Connecting Pharmaceutical Knowledge ispe.org

16

8
7/16/2020

Typical CIP Cycle Function

Pre-rinse  Removal of soluble and gross


residues
 Removal of soluble and dried
Alkaline
residues with cleaner, heat
cleaning
and/or wetting

 Removal of the suspended or


Water rinse
solubilized soiled and the
alkaline cleaner
 Removal of acid-soluble
Acid rinse
/inorganic soils and
neutralization of alkali residues
 Removal of all cleaner
Final rinse
residue and product residue

 Facilitate draining on low-


Air dry surface draining

Connecting Pharmaceutical Knowledge ispe.org

17

Equipment Surface & Design

• Dead Leg in piping and process connections


– an area of entrapment in vessel or piping run that could lead to
contamination of the product.
– Dead leg Orientation: pitched to drain
– There is evidence that an L/D of 2 or less may prevent the branch from
the dead leg (Ref: ASME BPE-2019)

CIP Solution
L/D < 2

Good Turbulence Intermediat No Turbulence


Good Mixing e Poor Mixing
Good Cleaning Turbulence Poor Cleaning
and Mixing Ref: Handbook, Cleaning in place; A guide to
cleaning technology in the food processing
industry

Connecting Pharmaceutical Knowledge ispe.org

18

9
7/16/2020

Equipment Surface & Design

• Coverage
– Shadow areas
– Riboflavin Testing

• Riboflavin Procedure:
– Coat with riboflavin (0.2 g/L)
– Observe with UV light while wet
– Dry and then short rinse cycle with water
– Observe with UV light while wet
– If poor coverage, make changes and repeat until 100% coverage

Connecting Pharmaceutical Knowledge ispe.org

19

Cleaning Design Space

Connecting Pharmaceutical Knowledge ispe.org

20

10
7/16/2020

Design Space (ICH Q8 R2)


• The multidimensional combination and interaction of input
variables (e.g., material attributes) and process parameters that
have been demonstrated to provide assurance of quality.

Product design

Continuous Improvement

Connecting Pharmaceutical Knowledge ispe.org

21

Process Knowledge

Key inputs and data are Consideration must be given to


analyzed and evaluated

- Product knowledge - Soil type


- Process knowledge - Process method, time, solubility, etc
- Regulations - Equipment design & configuration
- Quality Attributes - Utility impact, environmental, heat,
- Critical Processing pressure, etc
Parameters

Connecting Pharmaceutical Knowledge ispe.org

22

11
7/16/2020

Design Space

Critical Process Parameters Critical Quality Attributes (CQA’s)


(CPP’s)

- Temperature - Visual Inspection


- Cleaning action (manual) - Analytical Residue Limits
- Cleaning agent - Microbial Limits
- Cleaning agent - Drainability / Drying / Air Blows
concentration
- Clean Hold Time (CHT)
- Time
- Conductivity / pH
- Dirty Hold Time (DHT)

Connecting Pharmaceutical Knowledge ispe.org

23

Cleaning Design Space


• Cleaning process:
Products Critical Acceptable Values
Parameters of Parameters
Product A • Temperature 50°C, 10mins, 2%
• Cleaning agent alkaline cleaner
Product B • Concentration 50°C, 20mins, 2%
• Time alkaline cleaner

• Pre-requisite for Equipment &


Product grouping:

Connecting Pharmaceutical Knowledge ispe.org

24

12
7/16/2020

Soil Characterization

Connecting Pharmaceutical Knowledge ispe.org

25

Soil Characterization
Purpose: To understand characteristic of
soil
• Solubility in water/cleaning agent (pH ?)
• Toxicity, concentrations
• Excipients, degradants
• Verify suitability of current cleaning
methods / parameters
• Cleanability

Connecting Pharmaceutical Knowledge ispe.org

26

13
7/16/2020

pH solubility profile, pH 1 – 12

Connecting Pharmaceutical Knowledge ispe.org

27

Residues and Soils


• Actives, excipients, process materials, bioburden,
endotoxin
• Amounts of soils on surfaces
• Nature of soils on surfaces
– Freshly deposited Same soil, different process temperature
– Dried on during process
– Dried on during dirty hold time
– Baked on during process
– Compacted

~55% protein, 35% minerals, 6% fat~17% protein, 75% minerals, 6% fat

Connecting Pharmaceutical Knowledge ispe.org

28

14
7/16/2020

Type of Soils
Potential Residues for consideration:
• API (Drug substance)
• Excipients / Colorants / Dyes / Fragrances / Flavors
• Preservatives
• Degradants / Impurities
• Starting materials / Processing aids
• Mother liquors / Solvents
• Lubricants / antifoams - silicates
• Bioburden
• Mycoplasma / Prions / Viral particles
• Endotoxin

Connecting Pharmaceutical Knowledge ispe.org

29

How Do We Choose ?
Which materials represent the greatest risk to the next
process?
• High potency; high toxicity; allergenic
• Creates condition that is unacceptable to consumer (e.g.
off-color, abnormal fragrance, particulates)
• Hardest to clean / remove.
Is there justification to look for one residue as a “worst
case” when compared to other selected residues?
• Cleanability
• Toxicity
• Solubility
Based on risk assessment, perform qualification on
most difficult to clean products & product with the
lowest limit
Connecting Pharmaceutical Knowledge ispe.org

30

15
7/16/2020

Example (Dietary Supplements)

Cleanability in
Potency ‐ RDA Toxicity Total RPN
Oral Dosage Form Solubility (active) Alkaline
(mg) Oral LD50 (mg/kg) (S×P×T×C)
Detergent
Practically
Calcium 7
insoluble
1 800‐1200 1 6450 2 14
0.050‐
Chromium 4 Not specified 5
0.200
2 100‐400 2 80

Iron 3 Soluble 4 10‐15 2 319 4 96


Slightly
Magnesium 5
soluble
3 270‐400 1 4722 2 30
Not
Potassium 3 soluble 3
specified
1 7200 2 18

Selenium 7 Insoluble 5 0.200 3 4.8 ‐7.0 2 210

Zinc 3 Soluble 4 10‐15 1 5000 2 24

Connecting Pharmaceutical Knowledge ispe.org

31

Oral Solid Dosage

Connecting Pharmaceutical Knowledge ispe.org

32

16
7/16/2020

Warning Letter
5. A summary of updates to your cleaning validation
protocol to better incorporate conditions identified as worst
case. This should include but not be limited to evaluating
drugs that are of highest toxicity, drugs that are lowest
solubility in their cleaning solvents, drugs that have
characteristics that make them difficult to clean, and
swabbing of various equipment locations that are most
difficult to clean.

Warning Letter 320-19-44 (Sep 2019)

Connecting Pharmaceutical Knowledge ispe.org

33

Cleaning Mechanisms & Critical


Cleaning Parameters

Connecting Pharmaceutical Knowledge ispe.org

34

17
7/16/2020

Cleaning Agent Options

Water

Commodity Chemicals

Formulated Cleaners

Organic Solvents

Connecting Pharmaceutical Knowledge ispe.org

35

Cleaning Agent Options &


Cleaning Mechanisms

Water • Solubility

Commodity • Solubility
Chemicals • Hydrolysis

• Solubility Emulsification
Formulated • Hydrolysis Dispersion
Chemistry • Wetting Chelation

Connecting Pharmaceutical Knowledge ispe.org

36

18
7/16/2020

Cleaning Agent –
Formulated Detergent e.g. CIP100
Components Function

Water
- Reverse Osmosis
- De-Ionized Solvent - Dissolve
- Purified Water
- Water For Injection

Bases Alkalinity source, hydrolysis


Chelants Tie up calcium, iron

Dispersants Suspend solids

Oxidants Oxidize, kill microbes

Surfactants Wet, solubilize, emulsify, disperse

Connecting Pharmaceutical Knowledge ispe.org

37

• 7LP HRI& OHDQLQJ


Time • ' LUW\+ ROG7LP H
• & OHDQ+ ROG7LP H

• )RUFHWRGLVORGJHWKHUHVLGXHV
Action • & ,36SUD\Z DVKLQJP DQXDOFOHDQLQJ
3DUWVZ DVKLQJ8 OWUDVRQLF

• * HQHUDOO\KLJKHUWKHEHWWHU
• & ULWLFDOIRUZ D[ RLO\
Temperature H[FLSLHQWV
• 6WURQJLQIOXHQFHRQ
P HFKDQLVP RIFOHDQLQJ

Connecting Pharmaceutical Knowledge ispe.org

38

19
7/16/2020

• + LJKHUWKHEHWWHU,QYHUVHO\
SURSRUWLRQDOWRWLP HDQG
Concentration WHP SHUDWXUH
• 6XEVWUDWHFRP SDWLELOLW\

• $ONDOLQH
• $FLGLF
Chemistry • 1 HXWUDOS+
• $GGLWLYH

• 6XUIDFH
• 6RLOFRQGLWLRQV
Others • : DWHUTXDOLW\
• (QYLURQP HQWDOIDFWRUV

Connecting Pharmaceutical Knowledge ispe.org

39

Direct Impingement
by Spray Ball/
Spindle

Cascading Flow

CIP SKID

Agitated Immersion

Connecting Pharmaceutical Knowledge ispe.org

40

20
7/16/2020

Action
• Physical Removal: related to force on surface
• Helps to dislodge residues
• Limited in static spray balls
– Distribution device, not an impingement device

Static Spray Ball Rotary Spray Head Rotary Jet Head

Connecting Pharmaceutical Knowledge ispe.org

41

Direct
Impingement
by Spray Arm

Cascading Flow

Direct Impingement by
Spray Ball/Spindle

Connecting Pharmaceutical Knowledge ispe.org

42

21
7/16/2020

Critical Cleaning Parameters

Concentration has inverse relationship with


time and temperature

Higher generally better

Connecting Pharmaceutical Knowledge ispe.org

43

Selecting Cleaning Agents –


Issues to Consider
• Effective cleaning, broad spectrum
• Consistency, lot traceability, availability,
• Stability
• Analytical methods availability
• Low foaming for spray applications
• Low toxicity, safety, environmentally acceptable
• Substrate compatibility
• Free rinsing
• Technical support
• Other requirement, halal certification

Connecting Pharmaceutical Knowledge ispe.org

44

22
7/16/2020

Rinsability
Analytical methods (specific and non-specific)
Active components and non active components
Percent residue removal as a function of the number of rinses

120
100
80
60
40
20 Analyzable Surfactant
TOC
0
0 1 2 3 4 5

Connecting Pharmaceutical Knowledge ispe.org

45

Rinsability
Percent residue removal

120
100.0
95.0

10090.0
85.0
80.0
75.0
TOC
8070.0 Sodium (IC)
65.0
60.0 Potassium (IC)
%Removed

Titration
6055.0
50.0 Organic Acid
45.0 Chelant
40.0
4035.0
30.0
25.0 Analyzable Surfactant
2020.0
15.0
10.0 TOC
5.0
0 0.0
0 1 2 3 4 5
15

30

45

Rinse Time, seconds

Measurement of Organic and Inorganic Residues Recovered from


Surfaces, Journal of Validation Technology, Volume 6, Number 1,
November 1999.

Connecting Pharmaceutical Knowledge ispe.org

46

23
7/16/2020

Formulated Chemistries
• Why use formulated cleaner?
– Free-rinsing: less water usage; less total process time
120
Rinse Comparison using Titration Data
98.6

Weight percent removed during rinse


100

80.6
80

60
CIP100
NaOH
40

18.4
20

1.3 0.1 0.8 0 0 0 0.1


0
Rinse 1 Rinse 2 Rinse 3 Rinse 4 Final
Number of Rinses in 110 g purified water

Information from Lab Report No. 3268

Connecting Pharmaceutical Knowledge ispe.org

47

Cleaning Performance

Soil and Surface & Cleaning Factors


Residue Equipment Design
Wet Material of Cleaning agent
Dry construction Cleaner concentration
Baked Irregularities Time (wash, rinse, etc.)
Steamed Roughness Temperature (wash,
Compressed Flow rates rinse, etc.)
Dirty hold time Coverage Water quality
Composition Drainability Action
Amount Minimize dead legs Rinsing
Orientation of dead
legs
Valve selection
Insert selection

Connecting Pharmaceutical Knowledge ispe.org

48

24
7/16/2020

Optimization of Cleaning Parameters

Connecting Pharmaceutical Knowledge ispe.org

49

Lab Evaluation

Process And Cleaner Evaluation


(PACE)

T – Temperature
C - Chemistry
C - Concentration
Visual Check
T - Time
Waterbreak Free Test
Gravimetric Test

Connecting Pharmaceutical Knowledge ispe.org

50

25
7/16/2020

Acceptance Criteria

•Soiled Coupon Visual Failure •Water Break


Free Failure

Connecting Pharmaceutical Knowledge ispe.org

51

Acceptance Criteria

• Visual Inspection
• Water-break Free (WBF)
• Gravimetric (± 0.1 mg)

Connecting Pharmaceutical Knowledge ispe.org

52

26
7/16/2020

Advantages of Lab Scale Study

Same coupon, Same coupon,


different angle. different angle.

Both coupons Both coupons


wet dry

Connecting Pharmaceutical Knowledge ispe.org

53

Lab Scale Cleaning Evaluation


• Experimental design to vary parameters for optimization
• Start with agitated immersion: Calibrated digital
stirplate
• Vary detergent concentration and temperature
• Check cleaning progress at specific time intervals.
Concentration Temperature °C Time
1% 60 15
Temperature
1% 80 15
2% 60 15
2% 80 15 Concentration

1% 60 30
1% 80 30

Connecting Pharmaceutical Knowledge ispe.org

54

27
7/16/2020

CASE Study
Cell culture medium

Agitated Immersion 1

TIME/ VISUAL WATER


CLEANER CONC.
TEMPERATURE OBSERVATION BREAK-FREE

Sodium
0.5% v/v 60 min/ 60°C Light residue No
Hydroxide
Sodium
5% v/v 60 min/ 60°C Light residue No
Hydroxide
Acid detergent 1% v/v 60 min/ 60°C Light residue No
Alkaline
1% v/v 10 min/ 60°C Visually clean Yes
detergent

Alkaline
0.5% v/v 10 min/ 60°C Visually clean Yes
detergent

Connecting Pharmaceutical Knowledge ispe.org

55

Formulated Chemistries
• Harvest material, air-dried
– Proteins, salts, Antifoam, Tropolone, MHX

Water
Visual
Cleaner Conc. Time/Temp Break
Observation
Free
Sodium
5% v/v 90 min/ 60°C Visually Clean Yes
Hydroxide

CIP 100 0.5% v/v 10 min/ 60°C Visually clean Yes

Connecting Pharmaceutical Knowledge ispe.org

56

28
7/16/2020

Examples of Challenging soil

• Titanium dioxide
 Alkaline cleaner + Booster/Additive

• Enteric coating
 Alkaline / acidic cleaner

• Opadry
 Alkaline cleaner
 Spray wash
 Pre-soaked followed by manual scrub
• Paraffin Waxes
 Alkaline cleaner + Booster/Additive

Connecting Pharmaceutical Knowledge ispe.org

57

When to Perform Lab Scale


Evaluation ?
• A cleaning protocol is being developed for a new
product or process
• The current cleaning process is being upgraded or
improved
• To “trouble-shoot” problems in a current cleaning
process
• Establish a “worst-case” product in a group of
products
– Cleanability

Connecting Pharmaceutical Knowledge ispe.org

58

29
7/16/2020

Agenda – Part 2

• Analytical methods and Acceptance


limits
• Scale-up of cleaning process and
considerations for equipment train
• Strategies to overcome common
cleaning challenges

Connecting Pharmaceutical Knowledge ispe.org

59

Analytical Methods and Acceptance


Limits

Connecting Pharmaceutical Knowledge ispe.org

60

30
7/16/2020

CPPs and CQAs


Critical Performance Parameters (CPPs)
• Cleaning temperature
• Turbulence or flow (action)
• Cleaning agent concentration
• Process times (includes Dirty-hold)
Critical Quality Attributes (CQAs)
• Visual Inspection
• Analytical residue limits (HPLC or TOC)
• Microbial (Bioburden/Endotoxin)
• Conductivity/pH

Connecting Pharmaceutical Knowledge ispe.org


Copyright © 2014 STERIS Corporations. All Rights Reserved. CONFIDENTIAL and PROPRIETARY to STERIS Corporation

61

Swab Sampling
Swab pattern directions
Non-flat surfaces
Flat surfaces
Flip Swab

Flip Swab

Connecting Pharmaceutical Knowledge ispe.org62

62

31
7/16/2020

Swab / Rinse Recovery Studies


The goal is to demonstrate reproducibility and the
effectiveness of the method :
Recovery testing:

 Spike coupon with known amount


 Remove in swab or simulated rinse procedure
 For swab, desorption
 Analyze sample

Case 1 Case 2
Pipette with
rinse solution Spike
bottom of
SS beaker
directly
spiked
coupon
Recovery factor to be applied to
Clean collection Lab shaker
vessel • Acceptance limit, or
 > 90% excellent with no recovery factor • Actual result
 > 70 - 90% is good with recovery factor
 > 50 - 70% may be okay with recovery factor
 < 50% is questionable
 If recovery > 100%, default to 100%

Connecting Pharmaceutical Knowledge ispe.org

63

Acceptance Criteria (CQA)


Visually clean, depends on:

 Lighting
 Viewing angle
 Viewing distance
 Contrast of residue and surface
 Inspector’s eyesight

Dry or wet surface ?

Bioburden limit: Endotoxin limit:


Rinse sampling:  Typically measured in the final rinse
 WFI: 10CFU/100mL  Rinse sampling: 0.25 EU/mL
 PW : 100CFU/1mL

Connecting Pharmaceutical Knowledge ispe.org

64

32
7/16/2020

Health Based Limits


• ISPE Risk MaPP and recent EMA document
are two main advocates & EU GMP Annex 15
– ADE: Acceptable daily exposure
– PDE: Permitted daily exposure
• Refers to limits based on toxicological
evaluation
– Focuses on how carryover might cause harm.
– Value represents dose that is unlikely to cause an
adverse effect if an individual is exposed at this
dose every day for a lifetime
NOAEL  Weight Adjustment
PDE (mg/day)
F1F2F3F 4 F5
Connecting Pharmaceutical Knowledge ispe.org

65

Cleaning program strategy for acceptance criteria setting


Visually clean
+
Cleaning strategy Lowest MACO

Worst case active residue


=
Lowest MACO

Active residue proprietary


Therapeutic Portfolio
Toxicological
management Health
daily dose based based
Minimum therapeutic Minimum dose with kill Minimum dose with
dose that give a of 50% population toxicological and
pharmacological effect  (LD50) pharmacokinetic
1/1000th  NOAEL limit (NOAEL)  PDE/ADE
limit
MACO= TDD*MBS MACO= NOAEL *MBS MACO= PDE *MBS
TDDN * SF TDDN*SF TDDN
1/1000th LD50* BW NOAEL * BW
SF F1*F2*F3*F4*F5

Setting acceptance criteria (MACO)

Identify active residue


Extrinsic source of active residues:
Active and/or cleaner residue, material degradation, leachable/extractible
Intrinsic source of active residues:
Connecting Pharmaceutical ispe.org
Knowledge
Product intrinsic impurity

66

33
7/16/2020

Case Study: Application of PDE Limit

• Cleaning of Product A in a vessel


• Next product manufactured (Product B) in
the same vessel are as follows:
- Batch size: 50kg (50L)
- Surface area of vessel: 500,000 cm2
- Maximum daily dose : 5 mL (Liquid injectable)

Connecting Pharmaceutical Knowledge ispe.org

67

Case Study: Application of PDE Limit

Health-based PDE value for Product A is 5mg/day


Maximum Allowable Carryover, MAC (µg) =

PDE: (mg/day)
MBS: Minimum batch size of next product
manufactured in same equipment
TDDN: Maximum daily dose of next product

Connecting Pharmaceutical Knowledge ispe.org

68

34
7/16/2020

Case Study: Application of PDE Limit

, µ ,
Maximum Allowable Carryover, MAC (µg) =
MAC (µg) = 50,000,000 µg

Limit / Surface Area (µg/cm2) = MAC (µg) / Total Surface Area (cm2)
= 50,000,000 µg / 500,000 cm2
= 100 µg/cm2

Limit / swab (µg Product A): = Limit / surface area (µg/cm2) X Area
Swabbed (cm2)
= 100 µg/cm2 x 25 cm2
= 2,500 µg

Connecting Pharmaceutical Knowledge ispe.org

69

Case Study: Application of PDE Limit


Each swab is desorbed in 25mL of WFI
Limit per swab (ppb Product A)
= [Limit per swab (µg Product A) / 25mL] x 1000mL
= [2,500 µg / 25 mL] x 1000mL
= 100,000 ppb
= 100 ppm

TOC method
Limit per swab (ppb TOC) = Limit per swab (ppb Product A) x 0.1
[Carbon content is 10%]
= 100 ppm x 0.1
= 10 ppm

The TOC swab limit based on swab area of 25 cm2 is 10 ppm.

Connecting Pharmaceutical Knowledge ispe.org

70

35
7/16/2020

Process Capability and Limits


Q6. How can limits for cleaning purposes be established?
A: Although the EMA guideline (EMA/CHMP/CVMP/SWP/169430/2012)
may be used to justify cleaning limits (as per Introduction paragraph 3),
it is not intended to be used to set cleaning limits at the level of the
calculated HBEL.

The STV should be used with the process capability of the


cleaning process to establish the alert and action levels:

STV “A”
Residue Level

Action Limit
Process Capability (Cpk)

Process Control Limit

Individual Data Points

Connecting Pharmaceutical Knowledge ispe.org

71

Scale-up of cleaning process and


considerations for equipment train

Connecting Pharmaceutical Knowledge ispe.org

72

36
7/16/2020

Scale up and Fine Tune


• Choose one worst case tank / equipment
• Worst case is based on
– Distance of CIP skids from tank /
equipment
– Complexity of CIP circuits (no. of
turns, etc) or equipment
• Use actual soil/placebo/mock soil (with
justification)
• Dirty Hold Time
• Rinse and Swab sampling
• Critical Quality Attributes
– Visual Inspection
– Analytical residue limits (HPLC, TOC,
etc.)
– Microbial (Bioburden/Endotoxin)
– Conductivity/pH
• Verify if acceptance criteria are met
• Optimize the cleaning parameters

Connecting Pharmaceutical Knowledge ispe.org

73

Cleaning Cycle Development – Parts Washer

Connecting Pharmaceutical Knowledge ispe.org

74

37
7/16/2020

Equipment / Product Grouping


Equipment Product
Grouping Grouping

Same Similar product


equipment type type

Same cleaning Same


procedure equipment train

Identical
equipment of Same cleaning
same sizes / procedure
different sizes

Connecting Pharmaceutical Knowledge ispe.org

75

Strategy Approach - Example


Equipments
Cleaning SOP 1

Equipments group Cleaning SOP 2

Cleaning SOP 3

Product 1

Equipments group
Product 2
Cleaning SOP 1

Product 3

Determine MACO Determine worst case


worst case product to clean

3 runs?

Connecting Pharmaceutical Knowledge ispe.org

76

38
7/16/2020

Equipment Train

• Maximum Allowable Carryover (MAC)


• Sum of all residues on each piece of shared equipment
• Apportion the total MAC to various pieces of shared
equipment
Example:
• Vessels A and B have surface acceptance limit of
8µg/cm2, it can be split into 3µg/cm2 for vessel A,
and 5µg/cm2 for vessel B

Connecting Pharmaceutical Knowledge ispe.org

77

Equipment Shared Surfaces


• Shared surface area between 2 products is key
– The larger the surface area, the lower the limit
• Product A to product B
– Made on same equipment
– Product contact shared surface area
– Made on some common equipment
– Use the relevant product contact surface area

Product Equipment W Equipment X Equipment Y Equipment Z


A √ √ √
B √ √ √

Connecting Pharmaceutical Knowledge ispe.org

78

39
7/16/2020

Strategies to Overcome Cleaning


Challenges

Connecting Pharmaceutical Knowledge ispe.org

79

Common Cleaning Challenges for Pharmaceutical


and Biopharmaceutical Facilities

Air Liquid Derouging &


Slip Agents
Interface Passivation

Microbial
Micro-Pitting
Contamination

Connecting Pharmaceutical Knowledge ispe.org

80

40
7/16/2020

Cleaning Challenge #1
SLIP AGENTS

Connecting Pharmaceutical Knowledge ispe.org

81

Slip Agents
Raw material impurities
• Hydrocarbons (Steramide, Erucamide, Oleamide)
– Mold release agents used in processing of bags & and
equipment
– Prevents caking of powders
– Found on bags used for storage and transport
• Polymers (Teflon, Nylon, PTFE, Silicone, etc.)
– Equipment used in raw material manufacturing
– Bags or containers used for raw material storage
– Impurities from source material
• Mineral Silicates (Silica, Talc, Kaolin)
• Lubricants
• Valves, gaskets and tubing – (source for siloxanes)

Connecting Pharmaceutical Knowledge ispe.org

82

41
7/16/2020

Erucamide, stearamide, and oleamide


• Synthetic, commonly used slip-agents in the manufacture
of plastics
• Insoluble in water and most buffers.
• Tend to float at air/liquid interface
– Deposit on side wall of tanks at the meniscus levels

• Stable molecules
– In highly acidic or basic conditions, terminal amide group can deamidate to
form the parent fatty acid. The conversion of the fatty acid does not change
the solubility in water.
– rest of molecule is aliphatic and remains intact under these conditions, with
no production of smaller soluble fragments.

• Buffers used are aqueous and don’t solubilize these slip


agents

Connecting Pharmaceutical Knowledge ispe.org

83

Case Study – Slip Agents

Connecting Pharmaceutical Knowledge ispe.org

84

42
7/16/2020

Cleaning Challenge #2
AIR LIQUID INTERFACE (ALI)

Connecting Pharmaceutical Knowledge ispe.org

85

Case Study – Air Liquid Interface

Air Liquid
Interface (ALI) Air

Product

Cleaning air-liquid interface


-Increase temperature of cleaning (70-80oC)
-Increase cleaning agent concentration (3-5% v/v) –
e.g CIP100
-Use of an oxidizing agent to improve cleaning
(e.g Proklenz Booster)
-Increase impingement by rotating spray devices
focused on the air-liquid interface
-Increase the time of the initial pre-rinse

Connecting Pharmaceutical Knowledge ispe.org

86

43
7/16/2020

Biotech – Air Liquid Interface

Connecting Pharmaceutical Knowledge ispe.org

87

Biotech – Air Liquid Interface


MAB MFG using attached mammalian cells in MA, USA

Soil Cleaner Conc. Method Temp Time

Media CIP 100 1% v/v AI 60 C 15 min.

Cytopore 2 CIP 100 1% v/v AI 80 C 15 min.

Cell Culture CIP 100 1% v/v AI 60 C 30 min

A/L Residue CIP 100 4% v/v SW 80 C 1-4 hrs*

Connecting Pharmaceutical Knowledge ispe.org

88

44
7/16/2020

Cleaning Challenge #3
DEROUGING & PASSIVATION

Connecting Pharmaceutical Knowledge ispe.org

89

Types of Rouge
• Type 1
– Oxidized metal particles generated from external
sources by erosion or corrosion
– Easier to remove, can often be wiped off

Connecting Pharmaceutical Knowledge ispe.org

90

45
7/16/2020

Types of Rouge
• Type 2
– Rouge formed from in situ oxidation of stainless
steel
– Tightly adhered, could have underlying damage.

Connecting Pharmaceutical Knowledge ispe.org

91

Types of Rouge
• Type 3
– Black oxide rouge generated from high
temperature or steam
– Non-reactive, behaves like a passive layer

Connecting Pharmaceutical Knowledge ispe.org

92

46
7/16/2020

Causes of Rouge

 Inappropriate MOC. 316L is the best option


Surface finishing / Damaged surface
 Corrosive contaminant / environment:
Chloride , Sulfide
 Steam
High temperature
 Residue
 Inadequate cleaning procedure:
Remove effeciently residues
Optimal frequency of sanitization
 Lack of periodic Maintenance

Connecting Pharmaceutical Knowledge ispe.org93

93

Conventional Method

Derouging Cycle Conventional Method of


Derouging

Pre-Cleaning Using NaoH – 60min

Rinse 2 Rinse x 30min – 60min

Derouge Using Nitric Acid – 120min

Rinse 2 Rinse x 30min – 60min

Passivate Using Citric Acid – 60min

Final Rinse 3 Rinse x 30min – 90min

Total 450 min (7.5 hour)

Connecting Pharmaceutical Knowledge ispe.org

94

47
7/16/2020

Importance of Pre-Cleaning
Organic
Residue
Organic residues covering the
Stainless Steel rouge. Derouging will be ineffective

Formulated Alkaline Detergent


Step The use of a formulated alkaline
#1 to remove the organic soil to
Stainless Steel uncover the rouge

The use of an alkaline to


Stainless Steel remove the organic soil to
uncover the rouge

Step Formuated Acidic Detergent The use of an acidic cleaner to


#2 remove rouge and passivate at
Stainless Steel the same time

The shiny surface of SS restored


Passivated Stainless Steel and passivated

Connecting Pharmaceutical Knowledge ispe.org95

95

New Trending Method


Conventional Method of STERIS Method of
Derouging Cycle
Derouging Derouging

Using Formulated Alkaline


Pre-Cleaning Using NaoH – 60min
Detergent CIP100 – 30min

Rinse 2 Rinse x 30min – 60min 2 Rinse x 30min – 60min

Using Formulated Acidic


Derouge Using Nitric Acid – 120min Detergent CIP200 to derouge
and passivate – 60min

Rinse 2 Rinse x 30min – 60min Not needed

Passivate Using Citric Acid – 60min Not needed

Final Rinse 3 Rinse x 30min – 90min 2 Rinse x 30min – 60min

Total 450 min (7.5 hour) 210min (3.5hr)


*system that has average rouge in system
Connecting Pharmaceutical Knowledge ispe.org

96

48
7/16/2020

Case Study # 1

Rouge Remediation :
•15 – 20% Acidic based
detergent CIP200 at 70°C
for 3 – 4 hours.

Preventive Maintenance
•Now performed annually
•5 – 10% Acidic based
detergent CIP200 at 70°C
for 1 hour.

Connecting Pharmaceutical Knowledge ispe.org

97

Case Study # 2
– Multi-Effect Water Still Generator

ProKlenz Two CIP 200

Connecting Pharmaceutical Knowledge ispe.org

98

49
7/16/2020

Case Study # 3

Cleaning process: 5% Alkaline Cleaner CIP100@ 60°C for 2 hours


Derouging process: 25% Acid Cleaner CI200 re-circulating in the
process vessels and piping circuits @ 70-80°C for 9.5 hours.

Connecting Pharmaceutical Knowledge ispe.org

99

Case Study
#4 -
Mannual
Derouging

Connecting Pharmaceutical Knowledge ispe.org

100

50
7/16/2020

Case Study # 5 - Before

Connecting Pharmaceutical Knowledge ispe.org

101

Case Study # 5 - After

Descaling 5% Acidic Detergent CIP200 (Formulated)


@60DegC, 1 hour

Connecting Pharmaceutical Knowledge ispe.org

102

51
7/16/2020

Case Study # 6

Connecting Pharmaceutical Knowledge ispe.org

103

Cleaning Challenge #4
Corrosion in Buffer Tanks
Connecting Pharmaceutical Knowledge ispe.org

104

52
7/16/2020

Chlorides
• 300 Series Stainless Steel alloys are prone to
corrosion in the presence of chlorides
• Pitting corrosion is an electrochemical
oxidation-reduction process, which occurs in
the absence of the passive layer

105

Connecting Pharmaceutical Knowledge ispe.org

105

Micro-Pitting
• Pitting corrosion is the localized corrosion of a
metal surface confined to a point or small
area.
• Pitting is one of the most damaging forms of
corrosion.

Connecting Pharmaceutical Knowledge 106


ispe.org

106

53
7/16/2020

Micro-Pitting

Connecting Pharmaceutical Knowledge 107


ispe.org

107

Passivation
Over time, chromium oxide layer will
Chromium react with air to form deplete and stainless steel is prone to
chromium oxide – a passive protective attack by chemicals and corrosive
layer product, causing rouge

CrO CrO CrO CrO CrO


1 CrO Fe C 2 CrO Fe C
Stainless Steel is made from different
components includiung iron, carbon,
chromium

Passive Protective Layer Chromium


Oxide restored
Acidic Detergent
O2 CrO O2 O2 CrO
CrO CrO CrO
Cr
3 Cr
CrO Fe C Cr
CrO Fe C
Exposing stainless steel to CIP200
4 acidic detergent helps to remove the
rouge and bring the chromium to the
surface, reacting with oxygen to form
chromium oxide, the protective later
again

Connecting Pharmaceutical Knowledge ispe.org

108

54
7/16/2020

Koslow Test Kit – Field tool

Millivolts Indication (Light Color)


+1000 to -199 High Non-Passive Range (RED)
-200 to -400 Passive Range (GREEN)
-401 to -1000 Low Non-Passive Range (RED)

Connecting Pharmaceutical Knowledge 109


ispe.org

109

Case Study # 6 – Media Prep Tank

Connecting Pharmaceutical Knowledge ispe.org

110

55
7/16/2020

Connecting Pharmaceutical Knowledge 111 ispe.org

111

Cleaning Challenge #5
Microbial Contamination Control
– Biofilm
Connecting Pharmaceutical Knowledge ispe.org

112

56
7/16/2020

Biofilm Definition
 Biofilm is generally composed of multiple microorganism
encased in matrix extracellular polymetric susbstance
(EPS):
Conceptual drawing: Biofilm generation

 EPS increase the Microorganism resistance and ability


to survive in rude environment
Connecting Pharmaceutical Knowledge ispe.org

113

BIOFILM GENERATION

Source: Montana State University Center for Biofilm Engineering

Connecting Pharmaceutical Knowledge ispe.org

114

57
7/16/2020

Factors influencing biofilm


generation

Connecting Pharmaceutical Knowledge ispe.org

115

Revolutionary Breakthrough : Biofilm Removal


ProKlenz One
• Biofilm removal label claim in US
• Biofilm removal at a 5% concentration on a pre-
cleaned, non-porous, nonfood contact surface at
60°C for a contact time of 10 minutes
• This performance claim demonstrates the efficacy of
ProKlenz ONE as both a cleaner and disinfectant

• “To prevent the formation of biofilms, sterilization


or disinfection or regeneration of water systems
should be carried out according to a
predetermined schedule and also when
microbial counts exceed action and alert limits.”
Annex 1 Draft

Connecting Pharmaceutical Knowledge ispe.org

116

58
7/16/2020

Biofilm Remediation
I. Biofilm remediation will always use a combine strategy:
1. Use of alkaline cleaning chemistry to penetrate/denature EPS
 5% CIP100 at 60°C for 3 hours
2. Derouging & passivation, if required
 Acid cleaning and passivation using 15% acidic cleaner at 80 °C for 5
hours – CIP 200
3. Use of the sporicidal chemistry to sanitize the system
 Sanitization using sporicidal agent at 25 °C for 30 minutes, or
 Steam in place

II. Prevention of biofilm generation is a cycle process


 Engineering Design
 Optimal cleaning/sanitization frequency and procedure (TACT parameter)
 Optimal disinfection/sterilization frequency and procedure (TACT parameter)
 Appropriate cleaning detergent
 Routine trend analysis is also important

Connecting Pharmaceutical Knowledge ispe.org

117

Robust Cleaning Process

• Physical-chemical proprieties • Periodic stainless-steel

• Cleaning methods/parameters maintenance


• Rouge remediation and preventive
• Residue profile
and carryover measures

• Product category

• Slip agent
• Air Liquid Interface • Engineering design (sanitary)
• Trending
• Effective cleaning and
sanitization process

Connecting Pharmaceutical Knowledge ispe.org

118

59
7/16/2020

Equipment Cleaning Process


Development – Where and How to
Start ?

Richard Chai
Technical Service
Manager
STERIS Corporation
Richard_chai@steris.com

16 Oct 2018

Thank you !

Connecting Pharmaceutical Knowledge ispe.org

119

60

You might also like